Catalyst Dossier · compiled by CeliA 🧫

Bristol-Myers Squibb Company (BMY)

Pharmaceutical Preparations · market cap $110.3B · as of 2026-07-08

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-07-30

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Bristol-Myers Squibb (BMY) is a large-cap pharmaceutical company with ~$115.8B market cap, anchored by Eliquis (30% of 2025 revenue), Opdivo (21%), and Orencia (8%). The company generated $48.2B in 2025 revenue with $7.1B net income, but carries a heavy $36.9B net debt load, reflecting prior M&A activity. Key near-term catalysts include a Phase 3 readout for KarXT (November 2026, imp 9/10) and Ipilimumab (March 2027, imp 9/10), alongside a PDUFA decision for Camzyos in May 2027.

The catalyst path

2026-07-30Earningsimp 5/10
2026-11-01 (est.)Phase 3 · KarXTimp 9/10
2026-12-31 (est.)Phase 3imp 7/10
2027-02-05 (est.)Phase 2 · Nivolumabimp 7/10
2027-03-11 (est.)Phase 3 · Ipilimumabimp 9/10
2027-06-30 (est.)Phase 2 · Arlocabtagene Autoleucelimp 7/10
2027-07-08 (est.)PDUFA · Cyclophosphamideimp 8/10
2027-07-16 (est.)Phase 2 · Luspaterceptimp 7/10

Pipeline

Asset	Phase	Indication
Arlocabtagene Autoleucel	Phase 2	Multiple Myeloma
Rituximab	Phase 2	Lymphoma
CC-97540	Phase 2	Lupus Erythematosus, Systemic
Vinflunine	Phase 3	Bladder Cancer
Capecitabine	Phase 3	Breast Neoplasms
BMS-936558 (Nivolumab)	Phase 3	Melanoma
DCV/ASV/BMS-791325	Phase 3	Hepatitis C
adefovir	Phase 3	Hepatitis B
Cyclophosphamide	Phase 3	Relapsed or Refractory Multiple Myeloma (RRMM)
BMS-986489 (BMS-986012+Nivolumab)	Phase 3	Extensive-Stage Small Cell Lung Cancer
BMS-650032	Phase 2	Chronic Hepatitis C
Nivolumab	Phase 3	Brain Neoplasms
Ozanimod	Phase 3	Colitis, Ulcerative
Paclitaxel	Phase 3	Lung Cancer
Irinotecan	Phase 2	Metastatic Colorectal Cancer (MCRC)
Irbesartan	Phase 3	Congestive Heart Failure
Deucravacitinib	Phase 3	Plaque Psoriasis
MDX-010	Phase 2	Prostate Cancer
stavudine extended-release, lamivudine, efavirenz	Phase 3	HIV Infections
Enoxaparin	Phase 3	Venous Thrombosis

Price & technical context

3-month

+1.1%

6-month

+5.3%

12-month

+26.5%

52-wk range

$42.60–$62.37

vs 50-day MA

+3.3%

vs 200-day MA

+7.7%

Realized vol

28.4%

Max drawdown

-32.5%

Daily closes through 2026-07-15. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for BMY (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.